


Rabbit anti-Goat IgG (H+L) Secondary Antibody, HRP

Product Details	
Size	3 mg
Species Reactivity	Goat
Host/Isotype	Rabbit / IgG
Class	Polyclonal
Type	Secondary Antibody
Conjugate	HRP
Immunogen	Gamma Immunoglobulin
Form	Liquid
Concentration	1.5 mg/mL
Purification	Affinity chromatography
Storage buffer	PBS, pH 7.4, with 4mg/mL BSA, 40% glycerol
Contains	0.19% Kathon™ CG
Storage conditions	4° C
RRID	AB_2533922

Applications	Tested Dilution	Publications
Western Blot (WB)	1:5000-1:10,000	0 Publication
Immunohistochemistry (IHC)	-	0 Publication
Immunocytochemistry (ICC/IF)	-	0 Publication
ELISA (ELISA)	1:2,000-1:4,000	0 Publication
Miscellaneous PubMed (Misc)	-	0 Publication

A




Goat IgG (H+L) Secondary Antibody (61-1620) in WB

Western blot analysis of albumin expression in brain samples obtained from ipsilateral ischemic or contralateral non ischemic MCA areas after 90-min t-MCAO and p-MCAO (A,B). At 1 and 3 d post stroke, albumin expression levels in the ipsilateral ischemic MCA areas were significantly greater than in the contralateral non-ischemic MCA areas after 90-min t-MCAO and p-MCAO (B). At 7 d post stroke, albumin expression levels in the ipsilateral ischemic MCA areas were significantly greater than in the contralateral non-ischemic MCA areas after p-MCAO, but not 90-min t-MCAO (B). H&E staining was performed for mice after 90-min t-MCAO and p-MCAO. H&E staining indicated hemorrhagic transformation after 90-min t-MCAO at 3 d post stroke. (n = 18, for each model) (CE). A KaplanMeier curve showed that survival rates were not significantly different between the stroke models (n = 49 for t-MCAO, n = 56 for p-MCAO) (F). * p < 0.05 between brain regions (B) (n = 3, for each sample). Scale bars = 200 μm (D) and 20 μm (E). Abbreviations: contra, contralateral; H&E, hematoxylin and eosin; ipsi, ipsilateral; p-MCAO, permanent middle artery occlusion; t-MCAO, transient middle cerebral artery occlusion; MCA, middle cerebral artery. Image collected and cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/32492968>), licensed under a CC BY license.

Goat IgG (H+L) Secondary Antibody (61-1620) in WB


Western blot was performed using Rabbit anti-Goat IgG (H+L) Secondary Antibody, HRP (Product # 61-1620). Whole cell extracts of LnCaP (Lane 1, 2, 3, 4, 5), HeLa (Lane 6) and HaCaT (Lane 7) were electrophoresed using NuPAGE™ 4-12% Bis-Tris Protein Gel (Product # NP03222BOX). Resolved proteins were transferred onto a nitrocellulose membrane (Product # IB23001) by iBlot® 2 Dry Blotting System (Product # IB21001). The blot was probed with CD10 Polyclonal Antibody (Product # PA5-47075) and GAPDH Loading Control Monoclonal Antibody (GA1R) (Product # MA5-15738). Secondary antibodies (Product # 61-1620, 1:10,000) and (Product # A28177, 1:10,000) were used for detection of CD10 and GAPDH respectively. Chemiluminescent detection was performed using iBright™ FL1500 (Product # A44115).



Goat IgG (H+L) Secondary Antibody (61-1620) in WB

Treatment with A2AR antagonist decreases microglia reactivity in the retina of diabetic mice. (A) Retinal sections were stained with antibodies against Iba-1 (green) and MHC-II (red). Nuclei were stained with DAPI (blue). Representative images are depicted and arrows indicate some MHC-II+ Iba-1+ cells found in each condition. (B) Activated microglia (MHC-II+ Iba-1+ cells) were counted and normalized to the percentage of total microglial cells (Iba-1+ cells) from 7-9 animals. (C) The number of microglia per retinal section was counted. (D) TSPO protein levels were assessed by Western blot and the results are expressed as a ratio to -actin from 6-9 independent experiments. Representative Western blots are presented. Full length uncropped images are presented as Supplementary Fig. 1. One-way ANOVA test, followed by Holm-Šídák multiple comparison test. GCL: ganglion cell layer; INL: inner nuclear layer; ONL: outer nuclear layer. Scale bar: 100 μm. Image collected and cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/31748653>), licensed under a CC BY license.

D



View more figures on thermofisher.com

81 References

p300 nucleocytoplasmic shuttling underlies mTORC1 hyperactivation in Hutchinson-Gilford progeria syndrome. *Nat Cell Biol* (2024)

Cationic-nanogel nasal vaccine containing the ectodomain of RSV-small hydrophobic protein induces protective immunity in rodents. *NPJ Vaccines* (2023)

Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. *Nat Neurosci* (2023)

Detection of Inflammasome Activation in Murine Bone Marrow-Derived Macrophages Infected with Group A *Streptococcus*. *Methods Mol Biol* (2023)

Shotgun Proteomics of Co-Cultured Leukemic and Bone Marrow Stromal Cells from Different Species as a Preliminary Approach to Detect Intercellular Protein Transfer. *Proteomes* (2023)

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization. Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that any Product will conform to such model or sample. NO OTHER WARRANTIES, EXPRESS OR IMPLIED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT. BUYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPAIR, REPLACEMENT OF OR REFUND FOR THE NON-CONFORMING PRODUCT(S) AT SELLER'S SOLE OPTION. THERE IS NO OBLIGATION TO REPAIR, REPLACE OR REFUND FOR PRODUCTS AS THE RESULT OF (I) ACCIDENT, DISASTER OR EVENT OF FORCE MAJEURE, (II) MISUSE, FAULT OR NEGLIGENCE OF OR BY BUYER, (III) USE OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS. Unless otherwise expressly stated on the Product or in the documentation accompanying the Product, the Product is intended for research only and is not to be used for any other purpose, including without limitation, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses, or any type of consumption by or application to human or animals.